Showing results (181-190 of 282) with videos related to
Sort By:
Pageof 29
Cytometry. Part B, Clinical Cytometry|September 28, 2010
Variables affecting the quantitation of CD22 in neoplastic B cellsGregory A Jasper, Indu Arun, David Venzon, et al.Nature|July 20, 2010
Regulation of myeloid leukaemia by the cell-fate determinant MusashiTakahiro Ito, Hyog Young Kwon, Bryan Zimdahl, et al.Journal of Cancer Research and Clinical Oncology|February 23, 2018
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom studyDavid M Ross, Tamas Masszi, María Teresa Gómez Casares, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 11, 2013
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategiesDavid Avigan, Parameswaran Hari, Minoo Battiwalla, et al.Pediatric Blood & Cancer|February 19, 2016
Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or LeukemiasNirali N Shah, Melinda S Merchant, Diane E Cole, et al.Pharmacotherapy|February 13, 2013
Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotypeBrad Moriyama, Paul F Jarosinski, William D Figg, et al.Blood|August 9, 2011
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemiaNicola Esposito, Irene Colavita, Concetta Quintarelli, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity studyJorge E Cortes, Michele Baccarani, François Guilhot, et al.Journal of the National Cancer Institute|September 7, 2021
Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase InhibitorsKelly L Schoenbeck, Ehab Atallah, Li Lin, et al.Biopreservation and Biobanking|November 28, 2017
Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG ReportEra L Pogosova-Agadjanyan, Anna Moseley, Megan Othus, et al.Pageof 29